Latest Biotech News

BridgeBio reported that encaleret met primary and key secondary endpoints in a global Phase III study for autosomal dominant hypocalcemia type 1 (ADH1), with 76% of treated patients achieving...

Illumina reported $1.08 billion in Q3 revenues—roughly flat year‑over‑year—and beat adjusted EPS expectations with $1.34, citing strength in clinical sequencing outside China. The company raised...

Eli Lilly reported tirzepatide sales of $10.1 billion in Q3—surpassing prior drug sales leaders and making tirzepatide the world’s top‑selling medicine—then disclosed a $1.2 billion investment to...

10x Genomics launched the next generation of its Chromium Flex assay that scales single‑cell studies by enabling automation‑compatible plate‑based multiplexing—processing up to 384 samples and...

Thermo Fisher Scientific agreed to acquire data‑solutions company Clario for $8.9 billion in cash plus an additional $125 million contingent payment—bringing the deal to about $9.0–$9.4 billion...

Novo Nordisk made a surprise unsolicited bid that values Metsera at roughly $9 billion, prompting Metsera’s board to deem the proposal “superior” to Pfizer’s earlier agreement and giving Pfizer...

The U.S. Food and Drug Administration unveiled draft guidance and public statements aimed at trimming clinical requirements for biosimilars, proposing reduced reliance on comparative efficacy...

The U.S. Food and Drug Administration placed an official clinical hold on two Phase 3 trials of Intellia Therapeutics’ in vivo CRISPR candidate following a serious liver injury in a study...

Eli Lilly reported blockbuster third-quarter sales for tirzepatide products, prompting the company to raise its revenue outlook and plan a $1.2 billion factory in Puerto Rico to scale production...

Thermo Fisher Scientific announced a cash acquisition of Clario, a clinical-trial data solutions company, in a transaction valued at roughly $8.9 billion plus contingent payments. Thermo Fisher is...

10x Genomics launched a next-generation Chromium Flex assay that expands plate-based multiplexing to 384 samples and promises throughput up to hundreds of millions of cells per week. Early-access...

BridgeBio reported positive Phase III results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with a high proportion of patients...

Recursion delivered a whole‑genome microglia phenomap generated from tens of millions of cell images to Roche and Genentech under their AI drug‑discovery pact, triggering a $30 million milestone...

Gilead reported an 11% year‑over‑year decline in cell therapy revenue for marketed CAR‑T products and disclosed a strategic decision in its early‑stage lenacapavir program: after comparing two...

New analyses and commercial moves are reshaping how GLP‑1 medicines reach patients: a health‑economics review found potency and outcomes justify higher prices for weight‑loss GLP‑1s under some...

The U.S. Food and Drug Administration has placed a clinical hold on two Phase 3 trials of Intellia Therapeutics’ CRISPR candidate nexiguran ziclumeran after a participant experienced a grade‑4...

Novo Nordisk submitted an unsolicited offer valuing obesity biotech Metsera at up to $9 billion—outbidding Pfizer’s earlier agreement—and the company’s board has labeled the proposal a “superior...

Eli Lilly reported blockbuster demand for tirzepatide, prompting a revenue forecast raise after the drug posted record quarterly sales. The company said tirzepatide (sold as Mounjaro/Zepbound)...

The U.S. Food and Drug Administration published draft guidance proposing to eliminate routine comparative clinical efficacy trials for many biosimilars, a move designed to speed approvals and...

Thermo Fisher Scientific agreed to acquire clinical‑trial data and software firm Clario in a cash deal reportedly worth about $8.9 billion plus earnouts. The transaction aims to integrate Clario’s...